Article ID Journal Published Year Pages File Type
5628643 Epilepsy Research 2017 9 Pages PDF
Abstract
Based on level 2 evidence, RS is an efficacious treatment to control seizures in MTLE, possibly resulting in superior neuropsychological outcomes and quality of life metrics in selected subjects compared to microsurgery. RS has a better risk-benefit ratio for small hypothalamic hamartomas compared to surgical methods Delayed therapeutic effect resulting in ongoing seizures is associated with morbidity and mortality risk. Lack of level 1 evidence precludes the formation of guidelines at present.
Related Topics
Life Sciences Neuroscience Neurology
Authors
, , , , , , , , , , ,